- Home
- QNRX vs NCEL Comparison
QNRX vs NCEL Comparison
Compare QNRX & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNRX | NCEL |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 10.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | QNRX | NCEL |
|---|---|---|
| Price | $11.50 | $2.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.5K | ★ 195.9K |
| Earning Date | 11-06-2025 | 12-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.01 | $1.89 |
| 52 Week High | $41.80 | $7.64 |
Technical Indicators
Market Signals| Indicator | QNRX | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | N/A |
| Support Level | $10.88 | N/A |
| Resistance Level | $14.25 | N/A |
| Average True Range (ATR) | 0.96 | 0.00 |
| MACD | -0.27 | 0.00 |
| Stochastic Oscillator | 9.95 | 0.00 |
Price Performance
Historical ComparisonAbout QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.